Back to Results
First PageMeta Content
Benzoates / Carbamates / Abiraterone / Antiandrogens / Pyridines / Prostate cancer / Docetaxel / Cyclophosphamide / Cabazitaxel / Medicine / Chemistry / Organic chemistry


6.1 ABIRATERONE ACETATE, tablet, 250 mg, Zytiga®, Janssen-Cilag Pty Ltd Purpose of Application Authority required listing for abiraterone for treatment of metastatic castrate-resistant prostate cancer (mCRPC) after tre
Add to Reading List

Document Date: 2014-11-12 19:13:31

Open Document

File Size: 82,99 KB

Share Result on Facebook

City

Trial / Increment / /

Company

Medical Oncology Group of Australia / Fleming / Janssen-Cilag Pty Ltd / Secretariat / AB PLA Increment AB / Medical Oncology Group / Trial 302 (safety population) Fluid / ITT / /

Country

Australia / /

Currency

USD / /

Event

FDA Phase / /

Facility

Consumer Comments facility / /

IndustryTerm

treatment of metastatic prostatic cancer / treatment of patients with mCRPC whose disease / treatment of metastatic castration resistant prostate cancer / treatment of metastatic castrate-resistant prostate cancer / pharmaceutical / /

MedicalCondition

hypertension / cancer / disease / metastatic castrate-resistant prostate cancer / mildly symptomatic cancer / progressive disease / carcinoma / prostatic cancer / pain / prostate cancer / hypokalemia / metastases / tumours / /

MedicalTreatment

chemotherapy / /

Organization

World Health Organization / AB PLA / Application Authority / Medicare / /

Position

driver / physician / representative / /

Product

Manufacturer Abiraterone Tablet / prednisolone / flutamide / bicalutamide / prednisone / mitoxantrone / abiraterone / AAA-302 / /

PublishedMedium

Journal of Clinical Oncology / /

Region

New England / /

Technology

chemotherapy / /

SocialTag